Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Rheumatoid Arthritis
- Enrollment Status: Open
- Protocol: IMVT-1402-2601
- Drug: IMVT-1402
- Sponsor: Immunovant
- Description: A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Active, Difficult-to-treat, ACPA-Positive Rheumatoid Arthritis
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Rheumatoid Arthritis
- Enrollment Status: Closed
- Protocol: PRIMA-102 “Aqtual”
- Drug: N/A: Collection for Assessment of DMARD Initiation
- Sponsor: Aqtual
- Description: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with inadequate response or intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Rheumatoid Arthritis
- Enrollment Status: Closed
- Protocol: GS-US-417-0304
- Drug: Filgotinib
- Sponsor: Gilead
- Description: A Multicenter, Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Sjogren’s Syndrome
- Enrollment Status: Open
- Protocol: HZNP-DAZ-301, HZNP-DAZ-301 HZNP-DAZ-304 “Oasis”
- Drug: Dazodalibep
- Sponsor: Horizon/Amgen
- Description:
- 301 Description: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
- 303 Description: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State
- 304 Description: A Multicenter, Long term, Randomized, Extension Study to Evaluate Safety and Tolerability of Dazodalibep in Subjects with Sjögren’s Syndrome (SS)
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: M23-699
- Drug: Upadacitinib
- Sponsor: Abbvie
- Description: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
